Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ovaries01:26

Ovaries

1.3K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
1.3K
Ovarian Cycle01:27

Ovarian Cycle

1.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.8K
Oogenesis02:07

Oogenesis

64.3K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
64.3K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

2.7K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy.

European journal of cancer (Oxford, England : 1990)·2026
Same author

ADC-opoly in endometrial and cervical cancer: expanding the board.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

NPJ digital medicine·2026
Same author

HMC3 revealed: how much do these "Microglia" really tell us?

Frontiers in immunology·2026
Same author

Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.

Gynecologic oncology·2026
Same author

The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021-2025 State-of-the-Art Review of Clinical and Preclinical Evidence.

Pharmacology research & perspectives·2026
Same journal

Deescalation, Discontinuation, and Deimplementation Trials: Evaluating Whether and How to Do Less.

JAMA·2026
Same journal

Surgical and Endoscopic Therapies for GERD.

JAMA·2026
Same journal

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

JAMA·2026
Same journal

"Suturing": Love, Death, and Perfection's Limits.

JAMA·2026
Same journal

What Is Low Back Pain?

JAMA·2026
Same journal

From Silicon Valley to the Vatican-The Expanding Debate on AI Ethics.

JAMA·2026
See all related articles

Related Experiment Video

Updated: Sep 8, 2025

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

2.8K

Ovarian Cancer: A Review.

Giuseppe Caruso1,2,3, S John Weroha4, William Cliby1

  • 1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Mayo Clinic, Rochester, Minnesota.

JAMA
|July 21, 2025
PubMed
Summary
This summary is machine-generated.

Ovarian cancer, a leading cause of cancer death, often presents at advanced stages. Early detection and targeted therapies, including surgery, chemotherapy, and maintenance treatments like PARP inhibitors, improve survival rates for ovarian cancer patients.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.0K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

11.5K

Related Experiment Videos

Last Updated: Sep 8, 2025

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

2.8K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.0K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

11.5K

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Cancer Epidemiology

Background:

  • Ovarian cancer is the eighth most common cancer globally, with high-grade serous carcinoma being the predominant subtype.
  • Risk factors include older age, family history, endometriosis, and nulliparity, with hereditary factors (BRCA1/2) in 25% of cases.
  • Most patients present with nonspecific symptoms and advanced-stage disease, complicating diagnosis and treatment.

Purpose of the Study:

  • To review the epidemiology, risk factors, diagnosis, and treatment of ovarian cancer.
  • To highlight the challenges in early detection and the management of advanced-stage disease.
  • To discuss the role of current and emerging therapies in improving patient outcomes.

Main Methods:

  • Review of epidemiological data and clinical studies on ovarian cancer.
  • Analysis of diagnostic modalities including imaging and tumor markers.
  • Evaluation of treatment strategies for early and advanced-stage ovarian cancer, including surgery, chemotherapy, and targeted maintenance therapies.

Main Results:

  • Ovarian cancer diagnosis and mortality rates remain significant worldwide, with an estimated 20,890 US cases and 12,730 deaths in 2025.
  • High-grade serous ovarian cancer accounts for 70-80% of epithelial malignancies, with a median age at diagnosis of 63.
  • Despite high initial remission rates, approximately 75% of advanced-stage patients experience relapse within 2 years, though PARP inhibitors improve survival in BRCA-related cases.

Conclusions:

  • Ovarian cancer management requires a multi-faceted approach, integrating surgery, chemotherapy, and targeted therapies.
  • Advanced-stage disease at diagnosis presents a significant challenge, necessitating effective treatment strategies.
  • Ongoing research into novel therapeutic targets and early detection methods is crucial for improving long-term survival in ovarian cancer patients.